4d-310
Gene therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2020 (NCT04519749)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Alpha-galactosidase ASupplementation
GLA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05629559 | Phase 1/Phase 2 (Phase 2) | Oct 16, 2022 | 4D Molecular Therapeutics |
| NCT04519749 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2020 | 4D Molecular Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics | For profit | 2 | 2 | 1 | 2020 |
1 organizations
Page 1 / 1